Prime Medicine, Inc. (PRME) Stock Price & How to Invest
Last updated November 2026
Short answer
You can invest in Prime Medicine (PRME) by buying shares or fractional shares at any major broker, through an ETF that holds it, or as one holding in a thematic basket. Prime Medicine is a clinical-stage gene-editing biotech built around its prime editing platform, a search-and-replace approach to correcting genetic mutations, and the thesis rests on early liver-disease programs reaching the clinic and reading out. It is speculative and pre-revenue: it generates no product sales, runs large annual losses, and depends on data from programs that only entered the clinic in the second half of 2026: the FDA cleared the PM647 IND for Alpha-1 Antitrypsin Deficiency on September 24, 2026, and the first patient was dosed in the Phase 1/2 trial of PM577a for Wilson Disease on October 5, 2026. As of October 16, 2026 the stock closed at ~$3.47, down ~1.7% year to date and ~40.2% over one year, for a market value near ~$629 million. The biggest risk is that those programs fail or that the company must raise cash on dilutive terms before any of them succeeds.
PRME stock price
As of 2026-11-16, Prime Medicine, Inc. (PRME) last closed at $4.19, up 9.7% over the past year. Over the past 52 weeks it has traded between $2.70 and $5.36.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Prime Medicine, Inc.'s investor relations page. Walnut is informational, not investment advice.
PRME key stats
At $4.19 on November 16, 2026, Prime Medicine, Inc. (PRME) has a market cap of $760M.
- Market cap
- $760M
- Price to book
- 18.6
- Beta
- 2.15
Market cap, P/E and yield are measured at the $4.19 price on November 16, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.
What's new with Prime Medicine, Inc. (PRME)?
The last two weeks for Prime Medicine, Inc., as of November 17, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.
- PRME closed at $4.19 on November 16, 2026, down 2.6% over the past five trading days (from $4.30).
- On November 12, 2026, Prime Medicine, Inc. filed its quarterly report (10-Q) with the SEC. Read the 10-Q on sec.gov
- On November 12, 2026, Prime Medicine, Inc. filed an 8-K with the SEC reporting quarterly results (Item 2.02). Read the 8-K on sec.gov
- On November 12, 2026, Prime Medicine, Inc. filed an 8-K with the SEC reporting a material agreement (Item 1.01). Read the 8-K on sec.gov
- On November 10, 2026, Prime Medicine, Inc. filed an 8-K with the SEC reporting quarterly results and other events (Item 2.02, Item 8.01). Read the 8-K on sec.gov
Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.
What does Prime Medicine, Inc. (PRME) do?
Prime Medicine is a gene-editing company developing therapies based on prime editing, a technology that pairs a CRISPR-derived nickase with a reverse transcriptase to make targeted search-and-replace edits to DNA without cutting both strands. The platform is positioned to address a broad range of genetic mutations and to deliver one-time treatments, but as of 2026 the company has no approved products and no product revenue. Its economics are typical of clinical-stage biotech: heavy research and development spending, recurring net losses, and reliance on cash reserves, partnerships, and equity raises to fund operations. The second half of 2026 moved the story from preclinical to clinical: the FDA cleared the Investigational New Drug application for PM647 in Alpha-1 Antitrypsin Deficiency on September 24, 2026, and the first patient was dosed in a global Phase 1/2 trial of PM577a for H1069Q-mutated Wilson Disease on October 5, 2026. In Q2 2026 the company reported ~$1.15 million of collaboration revenue and a ~$42.1 million net loss (EPS ~-$0.24 versus a ~-$0.26 estimate). The shares rose ~11.2% over the month to October 16, 2026, closing at ~$3.47, but remain down ~1.7% for the year and ~40.2% over twelve months.
What's driving Prime Medicine, Inc. (PRME)?
Narrowed focus on a liver franchise
In 2025 the company restructured around in vivo liver targets, prioritizing PM577 for Wilson Disease and PM647 for Alpha-1 Antitrypsin Deficiency (AATD). Management guided to regulatory filings for both in 2026 and has largely delivered: the FDA cleared the PM647 IND on September 24, 2026, and the first patient was dosed with PM577a in a global Phase 1/2 Wilson Disease trial on October 5, 2026. Initial clinical data from both programs had been guided for 2027, so the next catalysts are enrollment updates and those first readouts.
Lead asset and FDA engagement
PM359, the company's program in Chronic Granulomatous Disease (CGD), generated early proof-of-concept data in patients, and Prime Medicine said it has been engaging the FDA about a potential path toward a Biologics License Application. The CGD effort was deprioritized as part of the liver pivot, but the early human data is cited as platform validation.
Bristol Myers Squibb collaboration
Prime Medicine has a research collaboration and license agreement with Bristol Myers Squibb to develop prime edited ex vivo T-cell therapies. The deal included an upfront payment of roughly ~$110 million and the potential for more than ~$3.5 billion in milestone payments over time, providing non-dilutive funding and external validation of the platform.
Platform breadth beyond current programs
The prime editing platform is designed to correct a large share of known disease-causing mutations, which the company frames as optionality across many indications. That breadth is a long-term thrust, but turning platform potential into approved products requires years of clinical work and substantial additional capital.
What are the risks to Prime Medicine, Inc. (PRME)?
Prime Medicine is pre-revenue and burns tens of millions of dollars per quarter, so the central risks are clinical and financial. As of March 31, 2026 the company reported roughly ~$149.2 million in cash, cash equivalents, investments, and restricted cash, which management expected to fund operations into 2027; by June 30, 2026 cash and equivalents stood near ~$95.1 million against ~$112.5 million of debt, and trailing operating cash burn was ~$156 million, implying that another financing will likely be needed and could dilute existing shareholders. Lead programs only entered the clinic in September and October 2026, so a failed readout, a delayed filing, or a safety setback could materially reduce the company's value. It also competes with better-capitalized gene-editing peers, some of which already have approved or later-stage products. Sentiment across gene editing is also volatile: in late September 2026 PRME, CRSP, NTLA, BEAM and EDIT all slipped on reports about AI-driven discovery tools before rebounding.
What is the Prime Medicine, Inc. (PRME) forecast?
11 analysts publish price targets on PRME, averaging $7.39 as of November 2026, or +76.4% against the $4.19 share price on November 16, 2026. The published targets run from $4.25 to $11.00, a wide spread, and the ratings split 11 buy, 3 hold, 0 sell. Over the last six months there have been 0 raises and 0 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.
Read the full PRME forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.
Is PRME a buy or a sell?
We give no verdict on Prime Medicine, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.
The case for buying. Narrowed focus on a liver franchise. In 2025 the company restructured around in vivo liver targets, prioritizing PM577 for Wilson Disease and PM647 for Alpha-1 Antitrypsin Deficiency (AATD). The most optimistic published target, $11.00, assumes this works close to its best case.
The case against. Prime Medicine is pre-revenue and burns tens of millions of dollars per quarter, so the central risks are clinical and financial. The most pessimistic target, $4.25, is roughly what PRME is worth if this bites instead.
Read the full bull and bear case on PRME, including what would have to change to break either one. Walnut is not an investment adviser.
Has Prime Medicine, Inc. (PRME) split its stock?
No. Prime Medicine, Inc. (PRME) has not split its stock in the last 10 years. The statement covers only the window we check, so an older split in the company’s history is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.
How is Prime Medicine, Inc. (PRME) valued?
Market cap, P/E and dividend yield at today's price are in the PRME key stats above. The business figures below come from Prime Medicine, Inc.'s reported results as of October 2026 and change when it next reports.
- Product revenue: None; collaboration revenue ~$4.1 million trailing twelve months (~$1.15 million in Q2 2026)
- Net loss: ~$187.9 million trailing; Q2 2026 net loss ~$42.1 million (EPS ~-$0.24 versus a ~-$0.26 estimate)
- Cash and debt (June 30, 2026): ~$95.1 million cash and equivalents against ~$112.5 million of debt
- Cash burn: Operating cash flow ~-$156 million trailing twelve months
- Analysts: 11 analysts, average target ~$7.11, consensus Strong Buy; 2026 EPS consensus ~-$0.94
- Next report: Q3 2026 results expected around November 6, 2026 (estimated date), EPS consensus ~-$0.23
As of October 2026: Prime Medicine is not profitable and is valued on its pipeline rather than earnings; a price-to-sales ratio near ~155x on collaboration revenue says little. The relevant numbers are cash against burn and the timing of the first clinical data from PM577a and PM647, which entered the clinic in September and October 2026. Figures are approximate as of October 16, 2026; check the latest filings for current numbers.
Who competes with Prime Medicine, Inc. (PRME)?
Base-editing companies
Beam Therapeutics is the most direct conceptual peer, using base editing to rewrite single DNA letters. Like Prime Medicine it targets indications such as AATD, but its lead programs are generally further along in Phase 1/2 testing.
In vivo and ex vivo CRISPR editors
Intellia Therapeutics focuses on in vivo CRISPR delivered by infusion and has later-stage programs, while CRISPR Therapeutics already co-markets the approved therapy Casgevy. Both are better capitalized and further along commercially than Prime Medicine.
Broader gene and cell therapy field
Prime Medicine also competes for capital and clinical relevance with the wider universe of gene and cell therapy developers and large pharma gene-editing efforts, several of which pursue overlapping liver and blood-cell indications.
What stocks are similar to Prime Medicine, Inc. (PRME)?
Other names that sit close to PRME: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.
How to invest in Prime Medicine, Inc. (PRME)
There are three common ways to get PRME exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so PRME sits alongside other stocks that express the same thesis.
Walnut takes the portfolio route. Describe a thesis where PRME fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.
The bottom line on Prime Medicine, Inc. (PRME)
If you believe prime editing can become a durable, one-time-treatment platform and that Prime Medicine's narrowed liver franchise will produce convincing early data, the question becomes sizing and overlap with the rest of your portfolio, not timing. This is a binary, pre-revenue story whose value hinges on clinical readouts that are still a year or more away, even though both liver programs crossed into the clinic in September and October 2026. The risk is that a program stumbles, that the cash runway forces a dilutive raise, or that competing gene-editing approaches reach patients first, any of which could sharply reduce the company's value regardless of the platform's long-term promise.
More on Prime Medicine, Inc. (PRME)
Whether PRME is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is PRME a buy or a sell?, and where the stock could go from here in the PRME stock forecast.
For income investors, whether PRME pays a dividend and how the payout looks is covered in does PRME pay a dividend? And to weigh PRME against a peer, read the full side-by-side comparisons: PRME vs BEAM and PRME vs DNA.
Wondering how PRME fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about Prime Medicine, Inc.
Ask Walnut's AI anything about PRME and see how it fits what you own.
FAQ
What does Prime Medicine do?
+
Prime Medicine is a clinical-stage biotechnology company developing gene-editing therapies based on its prime editing platform. Prime editing pairs a CRISPR-derived nickase with a reverse transcriptase to make precise search-and-replace edits to DNA. The company is focused on liver diseases such as Wilson Disease and Alpha-1 Antitrypsin Deficiency, aiming to create one-time genetic treatments. It currently has no approved products.
Is PRME a good stock to buy right now?
+
That depends on your own goals and risk tolerance, and this is not advice. As of October 16, 2026 PRME closed at ~$3.47, and 11 analysts average a ~$7.11 target. The bull case is that prime editing is a broad, validated platform and that early liver-program data in 2027 could be transformative. The bear case is that it is pre-revenue, burns tens of millions per quarter, faces likely dilution, and competes with better-funded peers. It is a high-risk, speculative biotech where a single readout can move the stock sharply.
Is PRME profitable?
+
No. Prime Medicine is pre-revenue and reported a net loss of roughly ~$49.1 million in the first quarter of 2026 and ~$42.1 million in the second, or ~$187.9 million over the trailing twelve months. Like most clinical-stage biotechs, it spends heavily on research and development while it has no approved products generating sales. Its income comes mainly from collaboration agreements rather than product revenue, and it is not expected to be profitable for years.
Does PRME pay a dividend?
+
No. Prime Medicine does not pay a dividend. It is a pre-revenue, clinical-stage biotech that reinvests its capital into research and development and relies on its cash reserves, partnerships, and equity financings to fund operations. Companies at this stage almost never pay dividends because they prioritize funding their pipelines over returning cash to shareholders.
What are Prime Medicine's lead programs?
+
As of 2026 the company's prioritized programs are PM577 for Wilson Disease and PM647 for Alpha-1 Antitrypsin Deficiency (AATD), both in vivo liver targets. The FDA cleared the PM647 IND on September 24, 2026, and the first patient was dosed in the PM577a Phase 1/2 trial on October 5, 2026; initial clinical data had been guided for 2027. PM359 in Chronic Granulomatous Disease produced early proof-of-concept data but was deprioritized in the strategic refocus.
How much cash does Prime Medicine have?
+
As of March 31, 2026, Prime Medicine reported roughly ~$149.2 million in cash, cash equivalents, investments, and restricted cash, which management said it expected to fund operations into 2027. At June 30, 2026 cash and equivalents were about ~$95.1 million, with ~$112.5 million of debt. Given its quarterly cash burn, the company will likely need to raise additional capital before any product reaches the market, which could dilute existing shareholders. Always check the latest filings for current figures.
Who are Prime Medicine's main competitors?
+
Prime Medicine competes with other gene-editing developers, including Beam Therapeutics in base editing, Intellia Therapeutics in in vivo CRISPR, and CRISPR Therapeutics, which co-markets the approved therapy Casgevy. Several of these peers are better capitalized and further along clinically. It also competes more broadly with the wider gene and cell therapy field and large pharma editing efforts.
How did Prime Medicine do in its latest quarter?
+
For Q2 2026 Prime Medicine reported ~$1.15 million of collaboration revenue and a net loss of ~$42.1 million, or ~-$0.24 per share, slightly better than the ~-$0.26 analysts expected and narrower than the ~$49.1 million loss in Q1. Since then the company has moved both liver programs into the clinic. Q3 2026 results are expected around November 6, 2026, with consensus EPS near ~-$0.23.
How has PRME stock performed in 2026?
+
PRME closed at ~$3.47 on October 16, 2026, down ~1.7% year to date and ~40.2% over one year, within a 52-week range of ~$2.67 to ~$6.30. The stock rose ~11.2% in the month to mid-October after the PM647 IND clearance and first PM577a dosing. Past moves say nothing reliable about future returns, and Walnut is not an investment adviser.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Prime Medicine, Inc.'s investor relations page or your broker before making investment decisions.